CN108804866A - 一种基于二元网络的心血管疾病药物与药靶的预测方法 - Google Patents
一种基于二元网络的心血管疾病药物与药靶的预测方法 Download PDFInfo
- Publication number
- CN108804866A CN108804866A CN201810952105.5A CN201810952105A CN108804866A CN 108804866 A CN108804866 A CN 108804866A CN 201810952105 A CN201810952105 A CN 201810952105A CN 108804866 A CN108804866 A CN 108804866A
- Authority
- CN
- China
- Prior art keywords
- drug
- medicine
- network
- target
- medicine target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 187
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 110
- 238000000034 method Methods 0.000 title claims abstract description 51
- 230000009977 dual effect Effects 0.000 title claims abstract 10
- 229940079593 drug Drugs 0.000 claims abstract description 128
- 239000002547 new drug Substances 0.000 claims abstract description 13
- 229940000406 drug candidate Drugs 0.000 claims abstract description 8
- 201000010099 disease Diseases 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 238000011160 research Methods 0.000 claims description 11
- 239000002327 cardiovascular agent Substances 0.000 claims description 6
- 229940125692 cardiovascular agent Drugs 0.000 claims description 6
- 229960000423 loxapine Drugs 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 claims description 3
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 claims description 2
- 102100040368 5-hydroxytryptamine receptor 6 Human genes 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims 2
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 claims 1
- 101710150235 5-hydroxytryptamine receptor 6 Proteins 0.000 claims 1
- 238000013528 artificial neural network Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229960001393 dosulepin Drugs 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000004850 protein–protein interaction Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 239000003596 drug target Substances 0.000 abstract description 126
- 238000009509 drug development Methods 0.000 abstract description 6
- 238000012216 screening Methods 0.000 abstract description 4
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 7
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 7
- 230000008569 process Effects 0.000 description 6
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000007781 pre-processing Methods 0.000 description 3
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 3
- 229960005080 warfarin Drugs 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 102100039126 5-hydroxytryptamine receptor 7 Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 108700039964 Duplicate Genes Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 101000761348 Homo sapiens 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
- 101000964051 Homo sapiens 5-hydroxytryptamine receptor 6 Proteins 0.000 description 1
- 101000744211 Homo sapiens 5-hydroxytryptamine receptor 7 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 230000005792 cardiovascular activity Effects 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960000589 loxapine succinate Drugs 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810952105.5A CN108804866B (zh) | 2018-08-21 | 2018-08-21 | 一种基于二元网络的心血管疾病药物与药靶的预测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810952105.5A CN108804866B (zh) | 2018-08-21 | 2018-08-21 | 一种基于二元网络的心血管疾病药物与药靶的预测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108804866A true CN108804866A (zh) | 2018-11-13 |
CN108804866B CN108804866B (zh) | 2019-09-20 |
Family
ID=64080578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810952105.5A Active CN108804866B (zh) | 2018-08-21 | 2018-08-21 | 一种基于二元网络的心血管疾病药物与药靶的预测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108804866B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109712678A (zh) * | 2018-12-12 | 2019-05-03 | 中国人民解放军军事科学院军事医学研究院 | 关系预测方法、装置及电子设备 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101441682A (zh) * | 2007-11-21 | 2009-05-27 | 上海生物信息技术研究中心 | 中药药效物质机理的生物信息分析平台及其分析方法 |
CN101670106A (zh) * | 2009-09-22 | 2010-03-17 | 吉林大学 | 可溶性鸟苷酸环化酶的天然激活剂 |
CN103065066A (zh) * | 2013-01-22 | 2013-04-24 | 四川大学 | 基于药物组合网络的药物联合作用预测方法 |
CN105144178A (zh) * | 2013-01-29 | 2015-12-09 | 分子健康股份有限公司 | 用于临床决策支持的系统和方法 |
CN105653846A (zh) * | 2015-12-25 | 2016-06-08 | 中南大学 | 基于集成的相似性度量和双向随机游走的药物重定位方法 |
CN106709272A (zh) * | 2016-12-26 | 2017-05-24 | 西安石油大学 | 基于决策模板预测药物‑靶蛋白相互作用关系的方法和系统 |
-
2018
- 2018-08-21 CN CN201810952105.5A patent/CN108804866B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101441682A (zh) * | 2007-11-21 | 2009-05-27 | 上海生物信息技术研究中心 | 中药药效物质机理的生物信息分析平台及其分析方法 |
CN101670106A (zh) * | 2009-09-22 | 2010-03-17 | 吉林大学 | 可溶性鸟苷酸环化酶的天然激活剂 |
CN103065066A (zh) * | 2013-01-22 | 2013-04-24 | 四川大学 | 基于药物组合网络的药物联合作用预测方法 |
CN105144178A (zh) * | 2013-01-29 | 2015-12-09 | 分子健康股份有限公司 | 用于临床决策支持的系统和方法 |
CN105653846A (zh) * | 2015-12-25 | 2016-06-08 | 中南大学 | 基于集成的相似性度量和双向随机游走的药物重定位方法 |
CN106709272A (zh) * | 2016-12-26 | 2017-05-24 | 西安石油大学 | 基于决策模板预测药物‑靶蛋白相互作用关系的方法和系统 |
Non-Patent Citations (2)
Title |
---|
MUHAMMED A YILDIRIM等: "Drug-target network", 《NATURE BIOTECHNOLOGY》 * |
苑婕 等: "基于随机森林算法的川芎成分-靶点-疾病网络的预测研究", 《中国中药杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109712678A (zh) * | 2018-12-12 | 2019-05-03 | 中国人民解放军军事科学院军事医学研究院 | 关系预测方法、装置及电子设备 |
CN109712678B (zh) * | 2018-12-12 | 2020-03-06 | 中国人民解放军军事科学院军事医学研究院 | 关系预测方法、装置及电子设备 |
Also Published As
Publication number | Publication date |
---|---|
CN108804866B (zh) | 2019-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Staszak et al. | Machine learning in drug design: Use of artificial intelligence to explore the chemical structure–biological activity relationship | |
Yamashita et al. | Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry | |
Pitkänen et al. | Past and present definitions of epileptogenesis and its biomarkers | |
Kinch et al. | Monoclonal antibodies: Trends in therapeutic success and commercial focus | |
US20200234810A1 (en) | Pharmacogenomic Decision Support for Modulators of the NMDA, Glycine, and AMPA Receptors | |
Sibilio et al. | In silico drug repurposing in COVID-19: A network-based analysis | |
CN110085325A (zh) | 关于中医经验数据的知识图谱的构建方法及装置 | |
CN106383992B (zh) | 疾病信息的处理方法 | |
Nikas | Inflammation and immune system activation in aging: a mathematical approach | |
Yang et al. | DNetDB: The human disease network database based on dysfunctional regulation mechanism | |
Gilvary et al. | A machine learning and network framework to discover new indications for small molecules | |
CN110853714A (zh) | 基于致病贡献网络分析的药物重定位模型 | |
Guzzi et al. | Analysis of age-dependent gene-expression in human tissues for studying diabetes comorbidities | |
CN108804866B (zh) | 一种基于二元网络的心血管疾病药物与药靶的预测方法 | |
Kop et al. | On the advantage of using dedicated data mining techniques to predict colorectal cancer | |
Lin et al. | Study on the mechanism of Liuwei Dihuang pills in treating Parkinson’s disease based on network pharmacology | |
Zhang et al. | Identification of proliferative diabetic retinopathy-associated genes on the protein–protein interaction network by using heat diffusion algorithm | |
Chen et al. | Integrated bioinformatics and clinical correlation analysis of key genes, pathways, and potential therapeutic agents related to diabetic nephropathy | |
Shen et al. | Bioinformatics and network pharmacology analysis of drug targets and mechanisms related to the comorbidity of epilepsy and migraine | |
Lee et al. | Evaluating current status of network pharmacology for herbal medicine focusing on identifying mechanisms and therapeutic effects | |
Mizutani et al. | Pharmacoepidemiological characterization of drug-induced adverse reaction clusters towards understanding of their mechanisms | |
Ni et al. | Mechanism of Tianma Gouteng Decoction in the treatment of Parkinson’s disease based on network pharmacology and molecular docking | |
CN114743599A (zh) | 一种基于组织特性网络的药物重定位方法 | |
CN108122005A (zh) | 一种临床药物层次分类的方法 | |
CN105787261B (zh) | 一种基于分子指纹图谱快速评估药物不良反应的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240422 Address after: No. 8, Shanding Road, Yubei District, Chongqing, 401120, China, 7-3-102 Patentee after: Chongqing Boshi Intellectual Property Service Co.,Ltd. Country or region after: China Address before: Dongshan West Road, Huainan City, Anhui Province Patentee before: HUAINAN NORMAL University Country or region before: China |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240509 Address after: Room 301, Building 3, No. 28 Juhai Second Road, Qujiang District, Quzhou City, Zhejiang Province, 324000 (temporary) Patentee after: Zhejiang fengneng Pharmaceutical Technology Co.,Ltd. Country or region after: China Address before: No. 8, Shanding Road, Yubei District, Chongqing, 401120, China, 7-3-102 Patentee before: Chongqing Boshi Intellectual Property Service Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |